Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oragenics ( (OGEN) ) has shared an announcement.
On May 27, 2025, Oragenics, Inc. announced a One-for-Thirty reverse stock split of its common stock, effective June 3, 2025, to maintain its listing on the NYSE American. This move aims to increase the market price per share, aligning with investor expectations and strengthening the company’s capital markets presence. The reverse stock split will not affect the company’s authorized shares or the par value of its common and preferred stock, but will adjust the number of shares and exercise prices of outstanding options and warrants.
Spark’s Take on OGEN Stock
According to Spark, TipRanks’ AI Analyst, OGEN is a Underperform.
Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock’s fundamental and technical weaknesses are significant, resulting in a low overall score.
To see Spark’s full report on OGEN stock, click here.
More about Oragenics
Oragenics, Inc. is a clinical-stage biotechnology company focused on developing breakthrough treatments for neurological disorders. The company’s lead asset, ONP-002, is an innovative intranasal therapy designed to address the unmet medical need in concussion treatment. Oragenics is committed to pioneering new approaches in neuroscience to improve patient outcomes.
Average Trading Volume: 358,096
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.12M
Find detailed analytics on OGEN stock on TipRanks’ Stock Analysis page.